What Megalase Treats: Main Uses and Benefits

Megalase is a medication used to address specific health conditions, offering clear therapeutic benefits. The medication is indicated for the palliative treatment of advanced breast cancer and advanced endometrial cancer (cancer originating in the lining of the uterus). This use focuses on managing symptoms and slowing disease progression in specific patient populations.

Another primary use for Megalase is in the management of anorexia, cachexia, or unexplained, significant weight loss in individuals who have received a diagnosis of Acquired Immunodeficiency Syndrome (AIDS). The key benefit in this context is the stimulation of appetite, which leads to weight gain and the mitigation of involuntary weight loss. Treatment with Megalase is generally initiated after other treatable causes of weight loss have been ruled out and addressed.

---

Quick Facts

• Treats: Advanced breast cancer and advanced endometrial cancer.
• Manages: Anorexia, cachexia, or unexplained, significant weight loss associated with AIDS.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility for Megalase: Official Regulatory Rules

Megalase is approved for use in adult patients for the palliative treatment of advanced breast or endometrial cancer, and for managing anorexia, cachexia, or unexplained, significant weight loss associated with Acquired Immunodeficiency Syndrome (AIDS).

Contraindicated Populations

The medicine is strictly contraindicated in two main groups as defined by regulatory documents:

• Patients with a known hypersensitivity to the active ingredient or any component of the formulation.
• Females with a known or suspected pregnancy; those of reproductive potential are advised to use effective contraception.

Restricted and Limited Use

Pediatric Use: Safety and effectiveness have not been established in the pediatric population.

Geriatric Use: Dose selection should be cautious in the elderly, reflecting the potential for decreased renal, hepatic, or cardiac function.

Conditional Use: The medicine requires caution in patients with a history of thromboembolic disease or those with pre-existing diabetes mellitus. For the weight loss indication, use is restricted until all other treatable causes of weight loss have been officially addressed. Nursing mothers are advised to discontinue breastfeeding if treatment with Megalase is necessary.

Megalase, which contains the active substance megestrol acetate, can interact with other medications, potentially altering the effects of either drug or increasing the risk of adverse reactions. It is crucial to inform your healthcare provider about all medicines, over-the-counter products, vitamins, and herbal supplements you are currently taking before starting Megalase treatment.

Major Interactions

The following medications are generally not recommended for use with Megalase due to the risk of serious side effects:

• Dofetilide: Taking dofetilide, a drug used to treat certain heart rhythm disorders, with megestrol acetate is contraindicated and can lead to dangerously irregular heartbeats.

Moderate Interactions

Close monitoring or dosage adjustments may be necessary when combining Megalase with these drug classes, as they may lead to a clinically significant interaction:

Drug Class	Potential Effect
Antidiabetic Agents (e.g., Insulin, Metformin)	Megalase may increase blood sugar levels, which could reduce the therapeutic effect of antidiabetic drugs.
Anticoagulants (e.g., Warfarin)	Megalase may increase the effect of blood thinners, raising the risk of bleeding.

Other Considerations

Megalase is also known to interact with indinavir (used for HIV/AIDS), which may require dose adjustment. Furthermore, due to its glucocorticoid-like activity, Megalase can suppress the adrenal glands, which may be exacerbated when combined with other drugs affecting the adrenal system. No known significant interactions exist between megestrol acetate and alcohol or common foods.

Enzymatic Hydrolysis of Extravascular Components

The core mechanism involves the enzyme Alpha-Amylase (alpha-Amylase) acting as a Glycoside Hydrolase (EC 3.2.1.1). Its primary biological target is the complex polysaccharides found within the inflammatory exudate (the fluid accumulated in the extravascular space). By initiating the hydrolysis (cleavage) of the alpha-1,4-glucosidic bonds in these large molecules, the enzyme breaks down the highly viscous components, which modifies the physical properties of the exudate in the extravascular space.

---

Modulation of Tissue Fluid Dynamics

The molecular action of liquefying the exudate initiates a physiological sequence that affects tissue fluid dynamics. The reduced viscosity of the exudate permits enhanced reabsorption and clearance of the fluid from the interstitial space through the capillaries and lymphatic system. Additionally, the mechanism is reported to have a modulatory effect that counters the abnormal increase in capillary permeability in the acute inflammatory state. These combined effects support the acceleration of interstitial fluid clearance and the reestablishment of fluid equilibrium in the local tissue.

How to Use Megalase

Megalase is an oral medication with administration principles strictly defined by regulatory documents, focusing on standardized dosing and frequency. The drug is available as coated tablets, syrup, and an oral solution. Treatment is generally continuous and is administered once daily (QD), typically without cycles. The preparation should be ingested without regard to meals.

Administration and Dosing

The official dosing schedule is determined by the specific approved indication and patient status. The established daily dosage for advanced cancer begins at 400 mg and may be maintained up to 800 mg once daily. For anorexia and cachexia associated with AIDS, the standard daily dose is typically 800 mg. The maximum recommended dose for any adult indication is 800 mg per day.

Special Instructions

To ensure proper delivery of the active ingredient, the coated tablets must be swallowed whole and must not be crushed, chewed, or divided. If the oral solution is used, it requires thorough shaking before measuring and administration. The continuation of therapy is subject to re-evaluation after two months of continuous use.

Population and Cessation Rules

Official instructions mandate specific adjustments for defined patient groups. For individuals with severe renal impairment (creatinine clearance < 20 mL/min), the dose must be reduced to 400 mg once daily. Megalase is not indicated for pediatric patients. When treatment is concluded, the official label requires a gradual dose tapering regimen.

Megalase: Recent Clinical Evidence

---

Evidence for Use in Advanced Cancer

Research examined the active ingredient's potential role in laboratory settings concerning advanced cancer. The existing studies are primarily non-clinical, such as cellular assays and in vitro experiments on tumor cell lines. These research efforts describe the enzyme's influence on cellular processes, and reported findings were derived entirely from non-human biological systems. Clinical outcomes, such as tumor response or changes in survival measures in human patients, are not characterized by dedicated, large-scale clinical trials. The relevance of non-clinical data to clinical outcomes in advanced human cancer is not established, and further human study is still emerging.

Evidence for Use in AIDS-Related Cachexia and Weight Loss

The active ingredient was evaluated in studies exploring its potential role in managing significant, unexplained weight loss (cachexia) associated with AIDS. The existing research base for this specific application is limited in authoritative summaries. Studies explored outcomes related to change in body weight, lean body mass (LBM), and patient-reported discomfort. The available evidence does not align with the robust structure of Randomized Controlled Trials (RCTs) found for other established options. The research often mentions the enzyme's role as a biomarker, and the durability of observed patterns is not well characterized.

Long-Term Studies and Extended Follow-up

Research has not fully established the long-term patterns related to this active ingredient. Follow-up durations were limited in initial studies, meaning there is insufficient information for long-term outcomes to describe how symptoms or physical parameters may evolve over time. Further research is ongoing or required to fully characterize long-term effects.

Evidence in Specific Patient Groups (Special Populations)

Research to date has provided limited insight into the evaluation of the active ingredient across certain patient groups. Results apply only to the populations studied, which may be narrow. Data for certain groups, such as children or pregnant populations, remain insufficient, and subgroup findings are uncertain due to limitations in the overall scope of the evidence.

What Is Still Uncertain About Megalase Research

The main gap in the evidence base includes the absence of high-quality randomized controlled trials (RCTs) designed specifically to measure clinical parameters in human patients for the approved uses. Comparative evidence is lacking, meaning the available studies have limited information on how this active ingredient compares to a placebo or other options. The overall certainty remains low, and more research is still emerging or required.

Key Studies & References

1. Amylase: MedlinePlus Medical Encyclopedia
2. Enzyme commission (EC) 3.2.1.1: Alpha-Amylase

Common questions about Megalase (FAQ)

Q: What does official guidance say about consuming alcohol during treatment with Megalase?

A: According to the official product information, there is no known significant interaction described between the active ingredient and alcohol. Guidance from regulatory sources indicates the importance of discussing the use of this medicine with alcohol with a healthcare professional.

Q: How soon after starting Megalase can a patient expect to see a change?

A: Regulatory information indicates that treatment is considered continuous and may be subject to re-evaluation after two months of use. The product summaries do not characterize specific timelines, such as days or weeks, for the onset of the effect.

Q: How will a patient know if the medication is working, based on official information?

A: Clinical studies relating to certain indications, such as unexplained weight loss, explored outcomes like a change in body weight, an increase in lean body mass (LBM), and improvements in patient-reported discomfort. These measures describe the parameters used in clinical settings to evaluate the medication’s effect.

Q: What warnings exist regarding taking Megalase with herbal supplements?

A: Official documents consistently emphasize the importance of informing a healthcare provider about all substances currently being taken, which includes vitamins, over-the-counter products, and herbal supplements. This information is requested to identify and mitigate any potential interactions that could alter how the medication works.

Q: How is the effectiveness of Megalase measured in studies?

A: Research supporting the medication has examined different measures depending on the indication. For specific conditions like cancer, evidence was examined on cellular processes (non-clinical data). For weight loss associated with AIDS, the evidence was examined by looking at changes in body weight, lean body mass, and patient-reported discomfort.

Q: Is Megalase available in a generic version, and how does it compare to the brand name?

A: Megalase is a preparation that contains the single active ingredient Alpha-Amylase (alpha-Amylase). The availability of a generic version or a brand/generic equivalent depends on local market regulations and is not detailed in the general product overview.

Q: Are there any special considerations for taking Megalase if a patient has a history of blood clots?

A: Yes, official regulatory text states that the use of Megalase requires specific caution in patients who have a history of thromboembolic disease (which involves blood clots). This history should be reviewed by a healthcare provider before initiating treatment.

Q: What are the differences between Megalase tablets and Megalase suspension, if applicable?

A: The medication is manufactured in several forms, including coated tablets, syrup, and an oral solution, to accommodate various patient groups. Regulatory instructions specify that tablets must be swallowed whole without crushing, while the liquid forms require thorough shaking before administration.

Q: Is Megalase generally prescribed for short-term use or long-term management?

A: The official product information describes the treatment as generally continuous. While some studies lack long-term data on the medication’s effects, the official labeling describes the regimen as generally continuous.

Q: Is Megalase a type of hormone medication, or how is its mechanism generally categorized?

A: Megalase is formally classified within the pharmacological class of Enzymes, specifically designated as a Glycoside Hydrolase (EC 3.2.1.1). It is not classified as a hormone medication.

Q: What is the official guidance on stopping Megalase if symptoms improve?

A: Official labeling requires a gradual dose tapering regimen when treatment is concluded. Any decision to stop the medication, including reasons such as symptom improvement, should be guided by the prescribing professional.

Q: Is it a common misunderstanding that Megalase works immediately upon taking it?

A: The product literature does not address specific patient misunderstandings. However, the fact that the treatment is continuous and may be subject to re-evaluation after two months suggests the medication’s intended full action is not immediate.

Storage and Disposal Requirements

Element	Official Regulatory Statement
Storage Temperature	Store at controlled room temperature, typically 25 C (77 F), with excursions permitted between 15 C to 30 C (59 F to 86 F).
Handling/Protection	Protect from heat and moisture. Avoid freezing. Tablets must be stored in the original package to protect from moisture.
Packaging	Keep the medication in its original container, which must be tightly closed.
Child Safety	Keep this medication out of the sight and reach of children.
Disposal	Dispose of any unused or expired medicinal product in accordance with local requirements. Do not dispose of via wastewater or household waste unless local regulations specifically permit it.

Regulatory requirements mandate storing Megalase under controlled room temperature conditions and protecting it from extreme heat, freezing, and moisture to preserve the product's quality. The container must be tightly closed. For safety, the product must be stored securely away from children. Official disposal instructions require discarding unused medicine in compliance with local pharmaceutical waste procedures.